GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.trihexyphenidyloxybutynin topical and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimipramineoxybutynin topical and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.trospium chlorideoxybutynin topical and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.vecuroniumoxybutynin topical and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.ziprasidoneoxybutynin topical decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.ziprasidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.zotepineoxybutynin topical decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.oxybutynin topical decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.Minor (20)acetaminophenoxybutynin topical decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.acetaminophen IVoxybutynin topical decreases levels of acetaminophen IV by unspecified interaction mechanism. Minor/Significance Unknown.acetaminophen rectaloxybutynin topical decreases levels of acetaminophen rectal by unspecified interaction mechanism. Minor/Significance Unknown.amantadineamantadine increases effects of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown.atenololatenolol increases levels of oxybutynin topical by decreasing metabolism. Minor/Significance Unknown.chlorpromazineoxybutynin topical increases toxicity of chlorpromazine by unspecified interaction mechanism. Minor/Significance Unknown.digoxinoxybutynin topical increases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.dimenhydrinatedimenhydrinate increases toxicity of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.donepezildonepezil decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.fluphenazineoxybutynin topical increases toxicity of fluphenazine by unspecified interaction mechanism. Minor/Significance Unknown.galantaminegalantamine decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.levodopaoxybutynin topical, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .perphenazineoxybutynin topical increases toxicity of perphenazine by unspecified interaction mechanism. Minor/Significance Unknown.prochlorperazineoxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.promazineoxybutynin topical increases toxicity of promazine by unspecified interaction mechanism. Minor/Significance Unknown.promethazineoxybutynin topical increases toxicity of promethazine by unspecified interaction mechanism. Minor/Significance Unknown.ruxolitiniboxybutynin topical will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.ruxolitinib topicaloxybutynin topical will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.thioridazineoxybutynin topical increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.trifluoperazineoxybutynin topical increases toxicity of trifluoperazine by unspecified interaction mechanism. Minor/Significance Unknown.abobotulinumtoxinAMonitor Closely (1)abobotulinumtoxinA increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.acetaminophenMinor (1)oxybutynin topical decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.acetaminophen IVMinor (1)oxybutynin topical decreases levels of acetaminophen IV by unspecified interaction mechanism. Minor/Significance Unknown.acetaminophen rectalMinor (1)oxybutynin topical decreases levels of acetaminophen rectal by unspecified interaction mechanism. Minor/Significance Unknown.aclidiniumMonitor Closely (1)oxybutynin topical and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.amantadineMonitor Closely (1)oxybutynin topical, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.Minor (1)amantadine increases effects of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown.amitriptylineMonitor Closely (1)oxybutynin topical and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.amoxapineMonitor Closely (1)oxybutynin topical and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.anticholinergic/sedative combosMonitor Closely (1)anticholinergic/sedative combos and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.aripiprazoleMonitor Closely (3)oxybutynin topical decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor. aripiprazole increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.atenololMinor (1)atenolol increases levels of oxybutynin topical by decreasing metabolism. Minor/Significance Unknown.atracuriumMonitor Closely (1)atracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.atropineMonitor Closely (1)atropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.atropine IV/IMMonitor Closely (1)atropine IV/IM and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.avapritinibMonitor Closely (1)oxybutynin topical will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.axitinibMonitor Closely (1)oxybutynin topical increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.belladonna alkaloidsMonitor Closely (1)belladonna alkaloids and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.belladonna and opiumMonitor Closely (1)belladonna and opium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.benperidolMonitor Closely (3)oxybutynin topical decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor. benperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.benztropineMonitor Closely (1)benztropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use. bethanecholMonitor Closely (1)bethanechol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.carbacholMonitor Closely (1)carbachol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.cevimelineMonitor Closely (1)cevimeline increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.chlorpromazineMonitor Closely (3)oxybutynin topical decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor. chlorpromazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)oxybutynin topical increases toxicity of chlorpromazine by unspecified interaction mechanism. Minor/Significance Unknown.cisatracuriumMonitor Closely (1)cisatracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.clomipramineMonitor Closely (1)oxybutynin topical and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.clozapineMonitor Closely (3)oxybutynin topical decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor. clozapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.cyclizineMonitor Closely (1)cyclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.cyclobenzaprineMonitor Closely (1)cyclobenzaprine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.darifenacinMonitor Closely (1)darifenacin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.desipramineMonitor Closely (1)oxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.dicyclomineMonitor Closely (1)dicyclomine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.digoxinMinor (1)oxybutynin topical increases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.dimenhydrinateMinor (1)dimenhydrinate increases toxicity of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.diphenhydramineMonitor Closely (1)diphenhydramine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.donepezilMonitor Closely (1)donepezil increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)donepezil decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.donepezil transdermalMonitor Closely (1)donepezil transdermal, oxybutynin topical. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.dosulepinMonitor Closely (1)oxybutynin topical and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.doxepinMonitor Closely (1)oxybutynin topical and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.droperidolMonitor Closely (3)oxybutynin topical decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor. droperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.echothiophate iodideMonitor Closely (1)echothiophate iodide increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.fesoterodineMonitor Closely (1)fesoterodine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.finerenoneMonitor Closely (1)oxybutynin topical will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.flavoxateMonitor Closely (1)flavoxate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.fluphenazineMonitor Closely (3)oxybutynin topical decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor. fluphenazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)oxybutynin topical increases toxicity of fluphenazine by unspecified interaction mechanism. Minor/Significance Unknown.galantamineMonitor Closely (1)galantamine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.Minor (1)galantamine decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.glycopyrrolateMonitor Closely (1)glycopyrrolate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.glycopyrrolate inhaledMonitor Closely (1)glycopyrrolate inhaled and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.haloperidolMonitor Closely (3)oxybutynin topical decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor. oxybutynin topical decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. haloperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.henbaneMonitor Closely (1)henbane and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.homatropineMonitor Closely (1)homatropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.huperzine AMonitor Closely (1)huperzine A increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.hyoscyamineMonitor Closely (1)hyoscyamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.hyoscyamine sprayMonitor Closely (1)hyoscyamine spray and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.iloperidoneMonitor Closely (3)oxybutynin topical decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor. iloperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.imipramineMonitor Closely (1)oxybutynin topical and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.ipratropiumMonitor Closely (1)ipratropium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.isavuconazonium sulfateMonitor Closely (1)oxybutynin topical will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.ivacaftorMonitor Closely (1)oxybutynin topical increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .levodopaMinor (1)oxybutynin topical, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .lofepramineMonitor Closely (1)oxybutynin topical and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.lomitapideMonitor Closely (1)oxybutynin topical increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.lonafarnibSerious - Use Alternative (1)oxybutynin topical will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.loxapineMonitor Closely (3)oxybutynin topical decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor. loxapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.loxapine inhaledMonitor Closely (2)loxapine inhaled increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. oxybutynin topical decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.maprotilineMonitor Closely (1)oxybutynin topical and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.meclizineMonitor Closely (1)meclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.methscopolamineMonitor Closely (1)methscopolamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.metoclopramideMonitor Closely (1)oxybutynin topical decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.neostigmineMonitor Closely (1)neostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.nitrofurantoinMonitor Closely (1)oxybutynin topical increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.nortriptylineMonitor Closely (1)oxybutynin topical and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.olanzapineMonitor Closely (3)oxybutynin topical decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor. olanzapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.onabotulinumtoxinAMonitor Closely (1)onabotulinumtoxinA and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.orphenadrineMonitor Closely (1)oxybutynin topical and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.oxybutyninMonitor Closely (1)oxybutynin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.paliperidoneMonitor Closely (3)oxybutynin topical decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. oxybutynin topical decreases levels